SIWA318H
/ SIWA Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 05, 2026
Diagnostic and therapeutic significance of selected antibodies against advanced glycation end-products (anti-AGEs).
(PubMed, Mol Biol Rep)
- "This paper discusses anti-MGO modified proteins, anti-imidazolone, anti-pentosidine, anti-CML (including SIWA318H), anti-CEL, anti-CMA, and anti-GA-pyridine antibodies, with a focus on their potential applications in diagnostics (biomarkers, disease progression monitoring) and therapy (e.g., SIWA318H in pancreatic cancer). The review also highlights current limitations, particularly regarding clinical use in humans, and outlines perspectives for further research in this promising field."
Biomarker • Journal • Review • Atherosclerosis • Cardiovascular • CNS Disorders • Diabetes • Metabolic Disorders • Oncology • Pancreatic Cancer • Solid Tumor
October 08, 2023
Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer.
(PubMed, Sci Rep)
- "Immunohistochemical analyses of the tumor tissues showed a significant decrease in senescent cells in the tumor microenvironment of SIWA318H treated mice compared to that of control treated mice (p < 0.05). These results provide compelling evidence that SIWA318H is a promising novel therapeutic against pancreatic cancer."
Journal • Metastases • Preclinical • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CD34
March 14, 2022
SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study
(PRNewswire)
- "SIWA Therapeutics, Inc...announced...that SIWA's proprietary humanized monoclonal antibody, SIWA318H, is efficacious in an immune competent humanized mouse xenograft model for pancreatic cancer...Both the SIWA318H high dose and low dose treatment groups showed significant anti-tumor activity in a PSN1 human pancreatic cancer mouse xenograft tumor model by significantly reducing tumor growth (P-Value < 0.0001)....it expects to file its first IND with the FDA in 2023 for pancreatic cancer."
IND • Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor
1 to 3
Of
3
Go to page
1